| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
389,580,000 |
| Market
Cap: |
43.08(B) |
| Last
Volume: |
4,690,332 |
Avg
Vol: |
1,930,532 |
| 52
Week Range: |
$75.49 - $140.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 487 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
71,005 |
274,979 |
309,595 |
581,627 |
| Total Sell Value |
$9,585,020 |
$36,298,507 |
$40,264,880 |
$70,726,419 |
| Total People Sold |
8 |
10 |
14 |
16 |
| Total Sell Transactions |
13 |
27 |
50 |
85 |
| End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Moy Jeffrey |
SVP, Operations |
• – – |
2018-03-12 |
4 |
D |
$60.73 |
$444,730 |
D/D |
(7,323) |
68,511 |
|
- |
|
| Leach Jacob Steven |
SVP, Research & Development |
• – – |
2018-03-12 |
4 |
D |
$60.73 |
$452,625 |
D/D |
(7,453) |
98,878 |
|
- |
|
| Doubleday Richard |
EVP, Chief Commercial Officer |
• – – |
2018-03-12 |
4 |
D |
$60.73 |
$565,280 |
D/D |
(9,308) |
94,429 |
|
- |
|
| Sayer Kevin R |
President & CEO |
• • – |
2018-03-12 |
4 |
D |
$60.73 |
$1,591,142 |
D/D |
(26,200) |
335,171 |
|
- |
|
| Ace Heather S |
SVP Human Resources |
• – – |
2018-03-12 |
4 |
D |
$60.73 |
$159,539 |
D/D |
(2,627) |
74,232 |
|
- |
|
| Pacelli Steven Robert |
EVP, Strategy & Corp. Dev. |
• – – |
2018-03-12 |
4 |
D |
$60.73 |
$552,527 |
D/D |
(9,098) |
125,830 |
|
- |
|
| Balo Andrew K |
EVP, Reg. Strategy, Clinical |
• – – |
2018-03-12 |
4 |
D |
$60.73 |
$578,095 |
D/D |
(9,519) |
108,567 |
|
- |
|
| Murphy Patrick Michael |
VP, Legal Aff & Chf Compl Ofcr |
• – – |
2018-03-08 |
4 |
A |
$0.00 |
$17 |
D/D |
16,817 |
49,948 |
|
- |
|
| Ace Heather S |
SVP Human Resources |
• – – |
2018-03-08 |
4 |
A |
$0.00 |
$30 |
D/D |
30,093 |
76,859 |
|
- |
|
| Pacelli Steven Robert |
EVP, Strategy & Corp. Dev. |
• – – |
2018-03-08 |
4 |
A |
$0.00 |
$39 |
D/D |
38,502 |
134,928 |
|
- |
|
| Moy Jeffrey |
SVP, Operations |
• – – |
2018-03-08 |
4 |
A |
$0.00 |
$30 |
D/D |
30,093 |
75,834 |
|
- |
|
| Abbey Donald |
EVP, Quality & Regulatory Afrs |
• – – |
2018-03-08 |
4 |
A |
$0.00 |
$39 |
D/D |
38,502 |
113,228 |
|
- |
|
| Sayer Kevin R |
President & CEO |
• • – |
2018-03-08 |
4 |
A |
$0.00 |
$81 |
D/D |
80,545 |
361,371 |
|
- |
|
| Blackford Quentin S. |
EVP, CFO, PFO & PAO |
• – – |
2018-03-08 |
4 |
A |
$0.00 |
$39 |
D/D |
38,502 |
102,258 |
|
- |
|
| Leach Jacob Steven |
SVP, Research & Development |
• – – |
2018-03-08 |
4 |
A |
$0.00 |
$30 |
D/D |
30,093 |
106,331 |
|
- |
|
| Gregg Terrance H |
Executive Chairman |
• • – |
2018-03-08 |
4 |
A |
$0.00 |
$47 |
D/D |
47,087 |
531,646 |
|
- |
|
| Doubleday Richard |
EVP, Chief Commercial Officer |
• – – |
2018-03-08 |
4 |
A |
$0.00 |
$39 |
D/D |
38,502 |
103,737 |
|
- |
|
| Balo Andrew K |
EVP, Reg. Strategy, Clinical |
• – – |
2018-03-08 |
4 |
A |
$0.00 |
$39 |
D/D |
38,502 |
118,086 |
|
- |
|
| Doubleday Richard |
EVP, Chief Commercial Officer |
• – – |
2018-02-23 |
4 |
AS |
$56.32 |
$92,252 |
I/I |
(1,638) |
13,972 |
|
- |
|
| Gregg Terrance H |
Executive Chairman |
• • – |
2018-02-15 |
4 |
AS |
$55.91 |
$559,095 |
I/I |
(10,000) |
20,882 |
|
- |
|
| Doubleday Richard |
EVP, Chief Commercial Officer |
• – – |
2018-01-23 |
4 |
AS |
$54.67 |
$89,384 |
I/I |
(1,635) |
15,610 |
|
- |
|
| Gregg Terrance H |
Executive Chairman |
• • – |
2018-01-16 |
4 |
AS |
$56.86 |
$568,588 |
I/I |
(10,000) |
30,882 |
|
- |
|
| Doubleday Richard |
EVP, Chief Commercial Officer |
• – – |
2017-12-26 |
4 |
S |
$56.39 |
$92,204 |
I/I |
(1,635) |
17,245 |
|
- |
|
| Sayer Kevin R |
President & CEO |
• • – |
2017-12-12 |
4 |
AS |
$58.85 |
$353,092 |
D/D |
(6,000) |
280,826 |
|
- |
|
| Balo Andrew K |
EVP, Reg. Strategy, Clinical |
• – – |
2017-12-11 |
4 |
AS |
$61.23 |
$198,691 |
D/D |
(3,245) |
79,547 |
|
- |
|
2309 Records found
|
|
Page 33 of 93 |
|
|
6.07 (5.2%) 
